Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-THEIA for non-infectious non-anterior uveitis
2020-000130-18Phase 3Active
- Sponsor
- Fundación para la Investigación Biomédica del Hospital Clínico San Carlos
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-infectious intermediate uveitis, Posterior uveitis (non-infectious) and uveitis comparing Methotrexate monotherapy, Adalimumab monotherapy and Adalimumab + methotrexate combination therapy (3 arms). Started Mar 2021; status: active.
02
Drugs
adalimumabmethotrexate
03
Conditions
non-infectious intermediate uveitisPosterior uveitis (non-infectious)uveitis
Beyond the preview
Go deeper on 2020-000130-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000130-18.